92779-77-6

Upstream product

• 4187-54-6 (R)-N-acetyl-1-(4-nitrophenyl)ethylamine 
• 177750-53-7 N-[(1R)-1-(4-bromophenyl)ethyl]acetamide 
• 1425504-35-3 (R)-N-(1-(4-(diphenylmethyleneamino)phenyl)ethyl)acetamide 
• 24358-62-1 (R)-1-(4-bromophenyl)ethylamine 
• 36283-44-0 N-acetyl-1-phenylethylamine 
• 42142-15-4 1-(4-nitro-phenyl)-ethylamine 
• 4187-53-5 (R)-2-methyl-p-nitrobenzylamine 

Downstream Products

• 1425504-13-7 (R)-N-(1-(4-(6-bromo-8-methoxyquinazolin-2-ylamino)-phenyl)ethyl)acetamide 
• 1425504-14-8 C₂₄H₂₃N₅O₂ 
• 100253-60-9 (R)-1-acetylamino-4-(1-acetylamino-ethyl)-benzene 

Relevant academic research and scientific papers

Quinazoline derivatives and its preparation method and application

The invention relates to quinazoline derivatives and its preparation method and application. The quinazoline derivatives with The structural formula, the quinazoline derivative to gefitinib for the positive control, the result shows that compared with the gefitinib has good activity; and lead compound OTS514 compared, equivalent activity, PBK/TOPK inhibitors for further transformation and the discovery of new anti-tumor medicine phenological shopping has higher learning with the reference value. The invention also provides a preparation method of the quinazoline derivatives and the preparation of PBK/TOPK inhibitor and an anticancer drug.

Discovery and optimization of a novel series of potent mutant B-Raf V600E selective kinase inhibitors

B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf